Drug Trial Radar · NCT05686070
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,327
Actual
Start
Jan 26, 2023
Primary completion
Oct 23, 2025
Study completion Oct 23, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: * an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or * TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together. Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting). The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it. Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health. Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months. Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned. During the study, the study team will: * Check vital signs such as blood pressure and heart rate * Examine the participants' heart health using an electrocardiogram (ECG) * Take blood samples * Ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
Conditions
- Prevention of Ischemic Stroke
- Acute Non-cardioembolic Ischemic Stroke
- High-risk Transient Ischemic Attack
Interventions
Asundexian (BAY2433334)Drug
Once daily, oral
PlaceboDrug
Placebo to asundexian, once daily, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of ischemic strokeTime frame: Up to 31 months
- Time to first occurrence of ISTH major bleedingTime frame: Up to 31 months
Locations
741 sites in 37 countries. Site status is shown where the registry gives one.
Eastern Shore Research Institute, LLC | Fairhope, AL
Fairhope, Alabama
Barrow Neurologic Institute - Petznick Stroke Center
Phoenix, Arizona
HonorHealth Research Institute
Scottsdale, Arizona
Banner - University Medical Center Tucson - Neurology
Tucson, Arizona
University of Arkansas for Medical Sciences - Neurology
Little Rock, Arkansas
Kaiser Permanente Fontana Medical Center
Fontana, California
Long Beach Medical Center - Neurology
Long Beach, California
Kaiser Permanente Los Angeles Medical Center - Neurology
Los Angeles, California
Los Angeles - USC Healthcare Center 2 - Neurology
Los Angeles, California
UCLA NeuroTranslational Research Center
Los Angeles, California
Hoag Memorial Hospital - Center for Research & Education
Newport Beach, California
UCI Medical Center - Neurology
Orange, California
San Francisco VA Health Care System
San Francisco, California
Cottage Health | Santa Barbara Cottage Hospital - Research Department
Santa Barbara, California
The Lundquist Institute - Neurology
Torrance, California
St. Vincent's Medical Center - Neurology Clinic
Bridgeport, Connecticut
Nuvance Health
Danbury, Connecticut
Yale University | School of Medicine - Department of Neurology
New Haven, Connecticut
ChristianaCare Health Services | Christiana Hospital - Emergency Medicine Research
Newark, Delaware
HCA Florida JFK Hospital - Neurology
Atlantis, Florida
Delray Medical Center - Neurology
Boynton Beach, Florida
Nova Clinical Research - Blake Medical Center
Bradenton, Florida
BayCare Health System | Morton Plant Hospital - Neuroscience Research department
Clearwater, Florida
UF Health Neuromedicine Hospital
Gainesville, Florida
Baptist Health Research Institute
Jacksonville, Florida
Intercoastal Medical Group | Clinical Research
Sarasota, Florida
USF Health South Tampa Center for Advanced Healthcare - Neurology
Tampa, Florida
BayCare Health System | Saint Joseph's Hospital - Neurology Department
Tampa, Florida
University of Illinois Hospital - Neurology
Chicago, Illinois
The University of Chicago Medical Center - Neurology
Chicago, Illinois
Loyola University Medical Center - Neurology
Maywood, Illinois
Mercyhealth Javon Bea Hospital - Riverside | Neurology Research Department
Rockford, Illinois
HSHS St. John's Hospital - Neurology
Springfield, Illinois
Baptist Health Lexington
Lexington, Kentucky
Ochsner Medical Center - New Orleans - Neurology
New Orleans, Louisiana
University of Maryland Medical Center - Neurology Care Center
Baltimore, Maryland
Tufts Medical Center - Neurology
Boston, Massachusetts
Henry Ford Hospital - Neurology
Detroit, Michigan
MSU Health Care Neurology & Ophthalmology
East Lansing, Michigan
Trinity Health | Oakland Hospital - Clinical Research Department
Pontiac, Michigan
Showing 40 of 741 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.